Demandez au CCPP


Demandez au CPPP est un système de questions-réponses qui vous permet de poser des questions de manière anonyme au CCPP. Ils publient ensuite régulièrement leurs réponses dans ces archives. Si votre question nécessite une attention plus immédiate, nous vous encourageons à contacter directement le CCPP. Veuillez vous assurer de poser votre question en anglais. Pour consulter le Code d’acceptation de la publicité du CCPP, veuillez cliquer ici.

Questions mises à jour jusqu’au: 30 avril 2021

Soumettre votre question de façon anonyme


Hi there. I submitted a question a few weeks ago regarding whether PAAB needed to review market authorization announcements that do not include any statement of the indication, however my question was not answered, so I am asking it again: Under the PAAB code, it is clear that under section 1.5(D) that a formulary announcement (i.e., now on provincial formulary") does not require PAAB review if it is not linked to a therapeutic message in any way and does not include a coverage criteria or code. However, it is not clear whether to same principle applies to a market authorization/NOC announcement. Does a message (in an email from a rep to a physician) containing only the message "Health Canada has authorized for sale" required PAAB review, if it is not linked to a therapeutic message? Can such a message include a basic link to the full, unedited Product Monograph (as approved by Health Canada) without PAAB review?

Please see PAAB document Pre-NOC Corporate/Editorial Communications for guidance.


We are currently waiting for approval for a new indication. Is there any way to disseminate unbranded disease information concerning this new indication before approval (ex: head office emails, medical emails, banner ads, etc.)?

Please see PAAB document Pre-NOC Corporate/Editorial Communications for guidance.


Hi there, I hope you are doing well! I'm wondering if an association/organization such as SOGC writes a letter endorsing a tool if that will suffice as an acceptable reference to support statements made in the piece. For background, our product has two indications but we do not have a study that supports both equally and therefore PAAB has said we cannot discuss both in the context of a patient profile. If the SOGC provides a letter stating that the use of this product for one patient (because of the benefit of both indications) is standard clinical practice would that help in approving the APS?

This appears to be a review case specific question. We suggest reaching out to the reviewer to determine what level of evidence/support would be required to support the copy in questions as it depends on the indication wording and how the patient case is being presented. In general, an association/organization letter will not supersede the Health Canada TMA or evidence requirements.


We are creating a clinical trial recruitment piece directed to patients evaluating the use of a marketed product for a new use. The study will evaluate the use of our product in combination with another marketed product and the inclusion criteria include the use of prior agents. To improve patient comprehension of the study and the inclusion criteria, we would like to include the marketed names of the combination product and the prior agents. However, the "Clinical Trial Recruitment" section of the Health Canada policy document "The Distinction Between Advertising and Other Activities" states 'no reference is made to the drug manufacturer's name, or to the name of the drug under investigation.' To clarify, does that mean we cannot include the marketed product name or the ingredient name of any agents in the piece?



To a currently marketed product, and instead of a "now available" message, the message is " has been granted market authorization for additional indications"? (Again, with or without a link to the updated PM Hi There. I've seen several questions that have circled this issue, but none that have addressed it head on: Is an electronic message to physicians that consists entirely of the message that a product has been granted market authorization (without mentioning the indication or therapeutic category), plus the sender's contact details, exempt from pre-clearance? Please assume the message will be sent by sales reps or commercial head office staff. What if this same message also includes a direct link to the product's unedited product monograph? What if the message relates to a label-extension)

A message of "now granted market authorization" is a claim that requires support and substantiation (authorized for what). This is different than a market access claim of "now available". The inclusion of the indication would automatically prompt at least lowest level fair balance. The same would apply to a label-extension. These messages would not be exempt. Please see Q&A 740.


Hello Are branded and help seeking search engine marketing campaigns allowed to run simultaneously if coming from different ad accounts and going to different landing pages?

If the regulations are followed, there would be no cross over between these two campaigns as the branded campaign could not include mention of therapeutic areas and the help seeking could not mention brand or manufacturer. No copy or links would be the same. Given this, yes, they could be run at the same time.

Retour en haut